Potential Role of APOBEC3 Family Proteins in SARS-CoV-2 Replication.

Potential Role of APOBEC3 Family Proteins in SARS-CoV-2 Replication.

Publication date: Jul 16, 2024

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has acquired multiple mutations since its emergence. Analyses of the SARS-CoV-2 genomes from infected patients exhibit a bias toward C-to-U mutations, which are suggested to be caused by the apolipoprotein B mRNA editing enzyme polypeptide-like 3 (APOBEC3, A3) cytosine deaminase proteins. However, the role of A3 enzymes in SARS-CoV-2 replication remains unclear. To address this question, we investigated the effect of A3 family proteins on SARS-CoV-2 replication in the myeloid leukemia cell line THP-1 lacking A3A to A3G genes. The Wuhan, BA. 1, and BA. 5 variants had comparable viral replication in parent and A3A-to-A3G-null THP-1 cells stably expressing angiotensin-converting enzyme 2 (ACE2) protein. On the other hand, the replication and infectivity of these variants were abolished in A3A-to-A3G-null THP-1-ACE2 cells in a series of passage experiments over 20 days. In contrast to previous reports, we observed no evidence of A3-induced SARS-CoV-2 mutagenesis in the passage experiments. Furthermore, our analysis of a large number of publicly available SARS-CoV-2 genomes did not reveal conclusive evidence for A3-induced mutagenesis. Our studies suggest that A3 family proteins can positively contribute to SARS-CoV-2 replication; however, this effect is deaminase-independent.

Open Access PDF

Concepts Keywords
Conclusive ACE2 protein, human
Enzymes Angiotensin-Converting Enzyme 2
Leukemia Angiotensin-Converting Enzyme 2
Parent APOBEC Deaminases
Viral APOBEC Deaminases
APOBEC3 family proteins
APOBEC3 proteins, human
COVID-19
Cytidine Deaminase
Cytidine Deaminase
deaminase-independent mechanism
Genome, Viral
Humans
Mutation
SARS-CoV-2
SARS-CoV-2
THP-1
THP-1 Cells
Virus Replication

Semantics

Type Source Name
disease IDO replication
disease VO Severe acute respiratory syndrome coronavirus 2
pathway REACTOME mRNA Editing
disease MESH myeloid leukemia
disease IDO cell
pathway KEGG Viral replication
drug DRUGBANK Angiotensin II
disease IDO infectivity
disease MESH Retrovirus Infection
disease VO USA
disease MESH COVID 19
disease MESH coronavirus infection
disease VO organization
disease MESH Emergency
disease IDO host
drug DRUGBANK Uracil
drug DRUGBANK Propylthiouracil
disease IDO immunodeficiency
drug DRUGBANK Coenzyme M
disease MESH herpes simplex
disease IDO susceptibility
disease MESH infection
disease VO URE
disease IDO assay
disease IDO production
drug DRUGBANK Aminosalicylic Acid
disease VO ORF
disease MESH Polio
drug DRUGBANK Altretamine
disease IDO blood
disease MESH acute monocytic leukemia
disease MESH respiratory diseases
drug DRUGBANK Streptomycin
disease VO Gag
drug DRUGBANK Dextrose unspecified form
disease MESH Infectious Diseases
disease VO titer
disease VO dose
drug DRUGBANK Timonacic
drug DRUGBANK Thiocolchicoside
drug DRUGBANK 5-amino-1 3 4-thiadiazole-2-thiol
disease VO TTC
drug DRUGBANK Trihexyphenidyl
disease VO gene
drug DRUGBANK Phosphate ion
drug DRUGBANK Potassium Chloride
drug DRUGBANK Tromethamine
drug DRUGBANK Glycerin
drug DRUGBANK Water
disease VO time
disease VO manufacturer
disease VO protocol
drug DRUGBANK Carboxymethylcellulose
drug DRUGBANK Methylene blue
drug DRUGBANK Tretamine
drug DRUGBANK Troleandomycin
disease MESH pneumonia
pathway KEGG Coronavirus disease
drug DRUGBANK Cytidine
disease VO Human immunodeficiency virus
disease VO efficient
disease IDO site
disease MESH influenza
disease MESH measles
pathway KEGG Measles
disease MESH mumps
disease MESH Point mutation
disease VO Env
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Guanosine
disease MESH hepatitis
disease VO dead
disease MESH viral infection
disease VO inactivation
disease MESH breast cancer
pathway KEGG Breast cancer
disease MESH cancer

Original Article

(Visited 1 times, 1 visits today)